Find in Library

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies globally, often detected at advanced stages which contribute to its high mortality rate. Recurrent and drug-resistant cases further complicate the therapeutic landscape, underscoring the urgent need for innovative treatment modalities. This review article addresses the transformative potential of antibody-drug conjugates (ADCs) as a novel therapeutic strategy for OC. ADCs, which combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, offer a targeted approach to cancer cell elimination with minimized damage to normal tissues. Among ADCs that demonstrated promising activity in OC are mirvetuximab soravtansine, luveltamab tazevibulin, upifitamab rilsodotin, trastuzumab deruxtecan, sacituzumab govitecan, datopotamab deruxtecan and tisotumab vedotin. Here, we provide an overview of the ADCs' mechanism of action, highlight the specific tumor cell antigens targeted and present a comprehensive evaluation of clinical trials that have assessed the efficacy and safety of various ADC candidates in patients with OC. PEER REVIEWED ARTICLE